6 results
* to describe the safety profile for qW, q2W and q3W regimens. * to determine the Maximum Tolerated Dose (MTD), if achieved (all regimens)* to describe the pharmacokinetics (PK) of single-agent RO6895882. Substudy BP28920/IMGThe study is designed to…
Study BP29541 is a first in-human, open-label, multicenter, dose-escalation Phase I clinical study of single-agent RO6958688. The study will be conducted in two parts. Part I of the study is single ascending dose in single patient cohorts to…
The primary objective is to evaluate the added value of the IntelLeg Knee on the execution of activities of daily living for individuals with a transfemoral amputation when compared to the use of an auto-adaptive or mechanical (non-powered)…
The primary objective is to compare the IntelLeg Knee on the execution of a subset of daily activities for individuals with a transfemoral amputation to auto-adaptive or mechanical (non-powered) prosthetic knee via musculoskeletal simulation. The…
The objective of this clinical study is to evaluate the impact of Multipoint Pacing (MPP) and SyncAV programming on ventricular electrical activation time and activation sequence using noninvasive electrocardiographic imaging (ECGi) in patients…
The primary objective of the study is to evaluate the efficacy of obinutuzumab(GA101) plus venetoclax (GVe) versus standard chemoimmunotherapy (BR/FCR)[concerning MRD negativity measured by flow cytometry in peripheral blood (PB)at month 15] and…